About Vivodyne
Vivodyne is a company based in Philadelphia (United States) founded in 2021 by Dan Huh. Vivodyne has raised $117.69 million across 3 funding rounds from investors including Khosla Ventures, CS Ventures and Kairos Ventures. Vivodyne offers products and services including Human Organ Models and Predictive AI. Vivodyne operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Adapsyn and Cellesce, among others.
- Headquarter Philadelphia, United States
- Founders Dan Huh
- SectorsHealthcare
- Email••••••••
- Website vivodyne.com
- Social LinkedIn X
- Legal Name Vivodyne, Inc.
- Total Equity Funding$117.69M (USD)
in 3 rounds
- Latest Funding Round$77.69M (USD), Series A
Feb 2025
- InvestorsKhosla Ventures
& 7 more
Products & Services of Vivodyne
Vivodyne offers a comprehensive portfolio of products and services, including Human Organ Models and Predictive AI.
Lab-grown tissues for realistic drug testing simulations
AI platform that optimizes therapies using human data
Funding Insights of Vivodyne
Vivodyne has successfully raised a total of $117.69M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $77.69 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $117.69M
- Total Rounds 3
- Last Round Series A — $77.69M
- First Round $2M
(Mar 2021)
- Investors Count 8
All 3 funding rounds of Vivodyne with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | $77.69M | Series A | – | Khosla Ventures | |
| Nov 2023 | $38M | Seed | – | Khosla Ventures | |
| Mar 2021 | $2M | Seed | – | – | – |
8 investors in total: 8 institutional.
Investors in Vivodyne
Vivodyne has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Khosla Ventures, CS Ventures and Kairos Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital firm focused on life sciences, physical sciences, and technology companies | – | kairosventures.com | Beverly Hills, United States | |
Investment in start-ups for global impact, with focus on B2B services and software solutions in India. | 2022 | csventures.in | Mumbai, India | |
Healthcare sector investments are managed by MBX Capital. | – | mbxcapital.com | New York, United States | |
Bison Ventures is focused on investing in frontier technology companies. | – | bison.vc | San Francisco, United States | |
- | – | helenacapital.vc | - | |
Venture capital investments are made in early-stage companies by Fortius Ventures. | – | fortiusventures.com | - | |
Investment management services are provided to professional investors worldwide. | – | lingotto.com | London, United Kingdom |
Investor details for Vivodyne
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vivodyne
14 people are tracked at Vivodyne (6 in leadership, 8 in team).
| Name | Role | Group |
|---|---|---|
Dan Huh | Co-Founder | Leadership |
Andrei Georgescu | Co-Founder, CEO & Board Member | Leadership |
Jonathan Galarraga | Director Of Tissue Model Development | Leadership |
Anthony Bahinski | Chief Technology Officer | Leadership |
Andrew McFarland | Vice President, Hardware And Automation | Leadership |
Tony Bahinski | Chief Biotechnology Officer | Leadership |
Vebjorn Ljosa | Principal Software Engineer | Team |
Jeffrey Libson | Strategic Advisor & Counsel | Team |
Rachel Bour | Lead Senior Scientist | Team |
Lisa Alpert | Senior Manager Business Operations | Team |
Lois Tolvinski | Senior Manager, Laboratory Operations | Team |
Nicolas Aziere | AI Scientist | Team |
Akash Chauhan | Hardware Engineer | Team |
James Melville | Principal Software Engineer | Team |
Complete people profiles for Vivodyne
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vivodyne
3 dated milestones of Vivodyne across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Vivodyne is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series A, of $77.7M.
Competitors of Vivodyne
Vivodyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Adapsyn and Cellesce, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| newcellsbiotech.co.uk | 2014 | Newcastle Upon Tyne, United Kingdom | $14.43M | 22 | Induced pluripotent stem cell-derived organoid models are developed for research. | |
| insphero.com | 2009 | Schlieren, Switzerland | $35.02M | – | Cell-based assays and 3D microtissues for drug screening are developed. | |
| pandorum.com | 2011 | Bengaluru, India | $36.82M | 28 | Regenerative medicine and 3D tissues are developed for therapeutic uses. | |
| adapsyn.com | 2016 | Hamilton, United States | – | – | Provider of computational tools for bacterial metabolomic and genomic data analysis | |
| cellesce.com | 2013 | Cardiff, United Kingdom | – | 9 | Scalable processes for organoid expansion are developed. | |
| vyantbio.com | 1999 | Cherry Hill, United States | $10.5M | 25 | Developer of drug discovery platform | |
| fluidformbio.com | 2017 | Waltham, United States | – | 19 | 3D bioprinting solutions for engineered tissues are developed. | |
| parallel.bio | 2020 | Cambridge, United States | $25.43M | 6 | Limited information available | |
| nextvivo.bio | 2021 | Palo Alto, United States | $7.9M | 8 | Immune-competent human-derived models are developed for drug discovery applications. |
Detailed competitors of Vivodyne
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vivodyne
The website of Vivodyne (vivodyne.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 52.2% vs previous month
Latest news on Vivodyne
Complete news archive for Vivodyne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Vivodyne
10 companies that operate in the same segment as Vivodyne (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vivodyne
Vivodyne was founded in 2021.
Vivodyne is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Vivodyne is a funded company, having raised a total of $117.69M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Mar 2021.
Vivodyne was founded in 2021 in Philadelphia, United States, within the biotechnology sector. An AI-driven platform is utilized to culture human tissue models for drug discovery purposes. Single-cell 4D phenomics is integrated with a confocal microscope, alongside an automated robotic system that identifies potential drugs and cellular therapies. Operations focus on advancing preclinical testing through engineered biological models.
Vivodyne's top competitors include Newcells Biotech, InSphero and Parallel Bio.
Vivodyne offers Human Organ Models and Predictive AI.
Vivodyne has 8 investors. Key investors include Khosla Ventures, CS Ventures, Kairos Ventures, MBX Capital, and Bison Ventures.
Vivodyne operates through Vivodyne, Inc..